Please assess the completion status of the following clinical trial:

Trial Title: Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 years of age~* Histologically or cytologically confirmed CRC that is metastatic~* Presence of BRAF V600E in tumor tissue determined by local assay at any time prior to screening~* Evidence of measurable disease as per RECIST, v1.1~* Subject able to receive cetuximab as per approved label with regards to RAS status~* Eastern Cooperative Oncology Group Status (ECOG) 0 or 1~* Adequate renal, hepatic, cardiac and bone marrow functions and adequate electrolytes as per protocol~* Subject able to take oral medications~Exclusion Criteria:~* Prior systemic therapy for metastatic disease~* Prior treatment with any RAF inhibitor, MEK inhibitor, cetuximab or other anti-EGFR inhibitors~* Symptomatic brain metastasis or Leptomeningeal disease~* History or current evidence of Retinal Vein Occlusion (RVO) or current risk factors for RVO~* History of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) ≤ 12 months prior to first dose.~* Impaired cardiovascular function or clinically significant cardiovascular diseases: history of myocardial infarction or coronary disorders within 6 months prior to start of study treatment, symptomatic congestive heart failure (grade 2 or higher), past or current clinically significant arrhythmia and/or conduction disorder within 6 months prior to study treatment start~* History of thromboembolic or cerebrovascular events within 6 months prior to start of study treatment~* Concurrent neuromuscular disorder that is associated with potential elevation of Creatine Kinase~* Known contraindication to cetuximab administration as per SPC/approved label

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 Arm (Type: EXPERIMENTAL): encorafenib plus binimetinib plus cetuximab

Based on this trial design, predict the completion outcome and termination type (if applicable).